Lynn S. Ashby

5.5k total citations
46 papers, 1.6k citations indexed

About

Lynn S. Ashby is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Lynn S. Ashby has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 17 papers in Pulmonary and Respiratory Medicine and 13 papers in Epidemiology. Recurrent topics in Lynn S. Ashby's work include Glioma Diagnosis and Treatment (33 papers), Brain Metastases and Treatment (17 papers) and Meningioma and schwannoma management (13 papers). Lynn S. Ashby is often cited by papers focused on Glioma Diagnosis and Treatment (33 papers), Brain Metastases and Treatment (17 papers) and Meningioma and schwannoma management (13 papers). Lynn S. Ashby collaborates with scholars based in United States, Canada and Italy. Lynn S. Ashby's co-authors include Kris A. Smith, Baldassarre Stea, David Brachman, Stephen W. Coons, William R. Shapiro, Nader Sanai, Jeffrey R. Wilson, Minesh P. Mehta, Robert F. Spetzler and Laura A. Snyder and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Cancer Research.

In The Last Decade

Lynn S. Ashby

43 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lynn S. Ashby United States	20	1.1k	591	361	348	304	46	1.6k
Jordonna Fulop United States	2	929 0.9×	340 0.6×	292 0.8×	294 0.8×	441 1.5×	2	1.6k
Jay‐Jiguang Zhu United States	25	1.0k 1.0×	283 0.5×	345 1.0×	283 0.8×	384 1.3×	88	1.7k
Hirohito Yano Japan	22	953 0.9×	384 0.6×	396 1.1×	321 0.9×	241 0.8×	86	1.7k
Naoki Kagawa Japan	26	734 0.7×	481 0.8×	191 0.5×	444 1.3×	377 1.2×	108	1.8k
Akshal Patel United States	9	666 0.6×	283 0.5×	304 0.8×	153 0.4×	277 0.9×	22	1.2k
Florian Stockhammer Germany	25	1.5k 1.4×	325 0.5×	475 1.3×	418 1.2×	522 1.7×	53	2.2k
Émeline Tabouret France	23	1.0k 1.0×	282 0.5×	604 1.7×	317 0.9×	401 1.3×	103	1.8k
Sean Grimm United States	24	1.2k 1.2×	315 0.5×	503 1.4×	900 2.6×	415 1.4×	79	2.1k
Elena Mazza Italy	24	722 0.7×	603 1.0×	518 1.4×	508 1.5×	234 0.8×	62	2.0k
Tiffany R. Hodges United States	19	722 0.7×	270 0.5×	289 0.8×	188 0.5×	316 1.0×	43	1.5k

Countries citing papers authored by Lynn S. Ashby

Since Specialization

Citations

This map shows the geographic impact of Lynn S. Ashby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn S. Ashby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn S. Ashby more than expected).

Fields of papers citing papers by Lynn S. Ashby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynn S. Ashby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn S. Ashby. The network helps show where Lynn S. Ashby may publish in the future.

Co-authorship network of co-authors of Lynn S. Ashby

This figure shows the co-authorship network connecting the top 25 collaborators of Lynn S. Ashby. A scholar is included among the top collaborators of Lynn S. Ashby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn S. Ashby. Lynn S. Ashby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fleming, Jessica L., Stephanie L. Pugh, Susan M. Chang, et al.. (2025). Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. International Journal of Radiation Oncology*Biology*Physics. 123(1). 84–92. 1 indexed citations

Schiff, David, Anne O’Neill, Paul D. Brown, et al.. (2024). LTBK-07. PROGRESSION-FREE AND OVERALL SURVIVAL RESULTS OF ECOG-ACRIN E3F05: A PHASE 3 INTERGROUP TRIAL OF RADIATION ± TEMOZOLOMIDE FOR GRADE II GLIOMAS. Neuro-Oncology. 26(Supplement_8). viii1–viii2. 4 indexed citations

Lassman, Andrew B., Khê Hoang‐Xuan, Mei‐Yin C. Polley, et al.. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology. 40(23). 2539–2545. 43 indexed citations

Rogers, Leland, Stephanie L. Pugh, Michael A. Vogelbaum, et al.. (2020). CTNI-57. LOW-RISK MENINGIOMA: OUTCOMES FROM NRG ONCOLOGY/RTOG 0539. Neuro-Oncology. 22(Supplement_2). ii55–ii56. 4 indexed citations

Rogers, Leland, Minhee Won, Michael A. Vogelbaum, et al.. (2019). High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. International Journal of Radiation Oncology*Biology*Physics. 106(4). 790–799. 114 indexed citations

Wefel, Jeffrey S., Stephanie L. Pugh, Ali Choucair, et al.. (2019). NCOG-01. NEUROCOGNITIVE FUNCTION (NCF) AND QUALITY OF LIFE (QOL) RESULTS FROM A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH RISK LOW-GRADE GLIOMAS. Neuro-Oncology. 21(Supplement_6). vi158–vi159. 5 indexed citations

Peereboom, David M., Burt Nabors, Priya Kumthekar, et al.. (2018). Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.. Journal of Clinical Oncology. 36(15_suppl). 2058–2058. 12 indexed citations

Dardis, Christopher, Kelly Milton, Lynn S. Ashby, et al.. (2017). Atypical Teratoid Rhabdoid Tumor: Two Case Reports and an Analysis of Adult Cases with Implications for Pathophysiology and Treatment. Frontiers in Neurology. 8. 247–247. 27 indexed citations

Weller, Michael, Nicholas Butowski, David Tran, et al.. (2016). ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA. Neuro-Oncology. 18(suppl_6). vi17–vi18. 41 indexed citations

10.

Ashby, Lynn S., Kris A. Smith, & Baldassarre Stea. (2016). Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World Journal of Surgical Oncology. 14(1). 225–225. 143 indexed citations

11.

Reardon, David A., James M. Schuster, David Tran, et al.. (2015). ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma.. Journal of Clinical Oncology. 33(15_suppl). 2009–2009. 59 indexed citations

12.

Nabors, Burt, Karen Fink, Tom Mikkelsen, et al.. (2015). Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro-Oncology. 17(5). 708–717. 180 indexed citations

13.

Dardis, Christopher, Kelly Milton, & Lynn S. Ashby. (2015). Whither thiotepa (for patients in the USA)?. Journal of Neuro-Oncology. 124(3). 529–530. 2 indexed citations

14.

Reardon, David A., James M. Schuster, David Tran, et al.. (2015). 107 ReACT. Neurosurgery. 62(Supplement 1). 198–199. 16 indexed citations

15.

Evans, Anna, Joseph C. Torkildson, Jana Portnow, et al.. (2014). Feasibility of an Attenuated Maintenance Chemotherapy Regimen Directed at Adolescents and Young Adults with Newly Diagnosed Localized Medulloblastoma and Other Central Nervous System Embryonal Tumors. Journal of Adolescent and Young Adult Oncology. 3(3). 106–111. 2 indexed citations

16.

Oppenlander, Mark E., Andrew B. Wolf, Laura A. Snyder, et al.. (2014). An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity. Journal of neurosurgery. 120(4). 846–853. 187 indexed citations

17.

Sankar, Tejas, Nina Z. Moore, Joshua B. Johnson, et al.. (2012). Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors. Journal of neurosurgery. 116(6). 1172–1181. 24 indexed citations

18.

Keep, Marcus F., et al.. (2006). Gamma Knife surgery targeting the centromedian nucleus of the thalamus for the palliative management of thalamic pain: durable response in stroke-induced thalamic pain syndrome. Journal of neurosurgery. 105(Supplement). 222–228. 13 indexed citations

19.

Keep, Marcus F., et al.. (2005). Gamma knife surgery for refractory postherpetic trigeminal neuralgia: targeting in one session both the retrogasserian trigeminal nerve and the centromedian nucleus of the thalamus. Journal of neurosurgery. 102. 276–282. 10 indexed citations

20.

Coons, Stephen W. & Lynn S. Ashby. (1999). PATHOLOGY OF INTRACRANIAL NEOPLASMS. Neuroimaging Clinics of North America. 9(4). 615–649. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact